DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the SUDEEP PHARMA LIMITED (SUDEEPPHRM) share price today?

SUDEEP PHARMA LIMITED (SUDEEPPHRM) is trading at ₹862.75 on the NSE, down 2.33% on the day. Source: DocStoX.

What is the PE ratio of SUDEEP PHARMA LIMITED?

SUDEEP PHARMA LIMITED has a price-to-earnings (PE) ratio of 56.4 in the Chemicals sector.

What is the market capitalisation of SUDEEP PHARMA LIMITED?

SUDEEP PHARMA LIMITED has a market capitalisation of approximately ₹9,788 crore.

SUDEEP PHARMA LIMITED

SUDEEPPHRM·NSE·Chemicals

₹862.75▼ -20.60 (-2.33%)

Chemicals · Pharmaceuticals

High-quality returns — 25% on equity

Day₹857.10

₹894.95

52W₹524

₹89591%

Open

₹883.00

High

₹894.95

Low

₹857.10

Prev Close

₹883.35

Volume

1.52L

VWAP

₹870.89

Snapshot

Key fundamentals

Market Cap

₹9,788 Cr

P/E Ratio

56.35Expensive

P/B Ratio

10.27

EPS

₹15.31

Book Value

₹78.20

ROE

25.20%Strong

ROCE

28.00%Efficient

Dividend Yield

0.19%

Debt / Equity

0.17Low

Face Value

₹1.00

52W High

₹894.95

52W Low

₹524.05

Sector

Chemicals

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹144

▼ 83.3%downside

Trading at ₹863 — 83% above our estimate

BearFair valueBull

₹122₹144₹165

/100

Business quality — Solid

Growth 79Profitability 100Efficiency 50Valuation 46

Plain English

Our view

High-quality returns — 25% on equity
Low debt relative to equity
Fundamental red flags (Piotroski 1/9)

Strengths

Low debt relative to equity
Strong returns on equity (25%)
Capital is working hard (ROCE 28%)
Profit growing 41% a year

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

25% ROE fading to 12% over ~10 yrs, on ₹78 book

₹138

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹164

Analyst target

No analyst coverage

—

Blended fair value₹144

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (25%)
Capital is working hard (ROCE 28%)
Profit growing 41% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

56.4Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

25.2%Strong

Above 15% is considered healthy for Indian equities

ROCE

28.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.17Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹9,788 Cr

P/B

10.27

EPS

₹15.31

Div Yield

0.19%

What changed

Recent changes

Foreign investors-0.1% stake last quarter
Domestic institutions+0.5% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 56.4×

Growth

Steady

+14% rev CAGR

Profitability

Excellent

25.2% ROE

Financial health

Rock solid

D/E 0.17

Momentum

N/A

No technicals

Today

Trading activity

Delivery %49.4%

Turnover₹1319.99L Cr

Trades10,053

VWAP₹870.89

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+14.4%

+24.5%

10Y

—

Profit

+41.0%

+39.5%

10Y

—

EPS

-67.4%

-42.2%

10Y

—

Profile

Pros

Company has delivered good profit growth of 39.0% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 31.8%

Watch-outs

Cons

Stock is trading at 10.5 times its book value

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.12 pts; domestic institutions added 0.51 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

76%

Promoter

Promoters

76.2%0.00

Public

3.1%-0.16

FII / FPI

1.6%-0.12

DII

18.1%+0.51

Others

1.1%

Total shareholders

36,503-7,096 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter76.15%

FII1.55%

DII18.11%

Public3.11%

Others1.08%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]